Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07801352 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This prospective, single-arm study aims to investigate the efficacy and safety of CapeOX combined with anti-PD1 antibody plus dihydroartemisinin as neoadjuvant or conversion therapy for pMMR/MSS locally advanced and metastatic colorectal cancer
Trial Details
NCT Number NCT07801352
Lead Sponsor Shanghai Changzheng Hospital
Conditions
(from sponsor)		 Locally Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Related terms Colorectal Neoplasms
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov